19 November 2025

Download (PDF - 164.6KB)

• Collaboration could expand GSK’s oncology portfolio with up to four potential first-in-class myeloid cell engagers across haematologic cancers and solid tumours
• LTZ’s novel immune-engager platform has the potential to combine potent cancer cell-killing with a safety profile to enable treatment in community settings
• Supports GSK's focus of using novel technologies in areas of disease expertise to advance medicines with transformative potential

GSK plc (LSE/NYSE: GSK) and LTZ Therapeutics (LTZ), an immunotherapy-focused biotechnology company based in Redwood City, California, today announced a strategic research collaboration to advance the development of novel myeloid cell engagers (MCEs) to address significant unmet need in oncology. The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development and commercial rights for these pre-clinical therapies.

MCEs are an emerging class of immuno-oncology treatments designed to use the body’s own immune system to recognise and kill tumour cells, providing a novel approach to target cancers with a favourable safety profile. Myeloid cells make up a significant majority of tissue resident immune cells in the body, providing potential for a broad and sustained infiltration of tumours when they are used to target and kill cancerous cells. The LTZ MCE platform has shown promising pre-clinical data on targeted anti-cancer activity in multiple tumour types. While other modalities have shown efficacy, they can be associated with significant side effects requiring inpatient monitoring that limit community use where most patients receive care. 

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: “This collaboration builds on GSK’s targeted investment in next-generation technologies to advance cancer medicines with transformative potential. By combining our scientific expertise with LTZ’s innovative immune-engager platform, we aim to accelerate first-in-class myeloid cell engager therapies in haematologic cancers and solid tumours to transform outcomes with a safety profile to enable broad community access for people living with cancer.”

Robert Li, Founder and CEO of LTZ said: “We are thrilled to enter a strategic agreement with GSK. This collaboration marks a pivotal milestone in our mission to uncover the potential of myeloid biology to deliver new treatment options for diseases with significant unmet need. Working with GSK for oncology indications will enable us to accelerate this vision, uniting expertise, and a common goal of improving outcomes for patients.”

Under the terms of the agreement, LTZ will receive an upfront payment of $50 million and is eligible to receive success-based preclinical, clinical, regulatory and commercial milestone payments, plus tiered royalties on global net sales of commercialized products resulting from the collaboration.

LTZ Therapeutics is an immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company's novel myeloid engager platform, to improve clinical outcomes in patients with cancer and autoimmune diseases. With main operations in Redwood City, California and Shenzhen China, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications. 

Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women’s cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q3 Results for 2025.